Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks (ALHC:NASDAQ)
Alignment Healthcare (ALHC) shares dropped almost 9% to $6.96 on Wednesday, coinciding with a broader weakness in Medicare Advantage stocks. This decline also impacted peers like Humana (HUM), which was down nearly 8%. The article indicates a general downturn in the Medicare Advantage sector.
ALHC Investors Have Opportunity to Join Alignment Healthcare, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following a whistleblower lawsuit filed on July 8, 2026. The lawsuit alleges that Alignment used accounting irregularities, specifically misclassifying operating expenses, to inflate its EBITDA for 2024 and 2025, which led to a 16.7% drop in the company's shares. SBS is inviting shareholders who suffered losses to participate in the fraud investigation.
Alignment Healthcare Faces Securities Fraud Probes
Alignment Healthcare (NASDAQ: ALHC) is under investigation by multiple securities law firms due to allegations of improper accounting practices and misleading financial disclosures. A whistleblower lawsuit filed by a former executive claims the company misclassified millions in operating expenses as capital expenditures to inflate adjusted EBITDA, which was linked to executive compensation. Alignment Healthcare denies the allegations, stating an outside review supported its accounting, and a federal judge has allowed significant claims in the whistleblower lawsuit to proceed.
ALHC Investors Have Opportunity to Join Alignment Healthcare, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following allegations of securities law violations. A whistleblower lawsuit filed on July 8, 2026, claimed the company used accounting irregularities to inflate its EBITDA for 2024 and 2025, leading to a 16.7% drop in Alignment's share price. Investors who experienced losses are encouraged to contact the firm to discuss their rights.
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Alignment Healthcare, Inc. (ALHC) following allegations that the company misclassified $8 million to $10 million in operating expenses as capital expenditures to inflate its stock price and executive compensation. The investigation also stems from a recent downgrade of the company's H3815 contract Star Rating by CMS, making it ineligible for quality bonus payments, which led to a significant decline in share price. KSF is examining whether Alignment's officers and/or directors breached their fiduciary duties or violated state/federal laws.
How (ALHC) Movements Inform Risk Allocation Models
This article analyzes Alignment Healthcare Inc. (NASDAQ: ALHC) using AI models, identifying near-term strong sentiment potentially challenging persistent mid and long-term weakness. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop loss levels. The analysis highlights a significant 204.5:1 risk-reward setup targeting a 57.9% gain with minimal risk, despite prevailing weak sentiment.
Alignment Healthcare EVP sells $35,496 in stock for tax obligations
Joseph S. Konowiecki, EVP of Corporate Affairs and a Director at Alignment Healthcare (NASDAQ:ALHC), sold 4,930 shares of common stock for $35,496 on November 10, 2026. This sale was to cover tax withholding obligations related to restricted stock unit vesting, not a discretionary trade. The company's stock has declined 59% in the past six months, but InvestingPro analysis suggests it is undervalued.
ALHC Investigation Ongoing: BFA Law Reminds Alignment
Bleichmar Fonti & Auld LLP (BFA Law) has launched an investigation into Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud. The investigation stems from allegations that Alignment artificially inflated its adjusted EBITDA to boost executive compensation, leading to a significant 16.7% stock drop on July 8, 2026. Investors who have incurred losses are encouraged to contact BFA Law to discuss their legal options in a potential class action lawsuit.
Alignment Healthcare EVP sells $35,496 in stock for tax obligations By Investing.com
Joseph S. Konowiecki, EVP of Corporate Affairs and Director at Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 4,930 shares of common stock for $35,496 on November 10, 2026. This transaction was not discretionary but rather to cover tax withholding obligations related to restricted stock unit vesting. Despite a 59% stock decline over six months, InvestingPro suggests the company is undervalued.
An EVP's required sale of 4,930 shares covers vesting taxes at Alignment Healthcare (ALHC).
Joseph S. Konowiecki, EVP of Corporate Affairs at Alignment Healthcare (ALHC), sold 4,930 shares of common stock at $7.20 per share on November 10, 2026. This transaction was not discretionary but was a required sale to cover tax withholding obligations related to the vesting of restricted stock units. Following the sale, Konowiecki directly held 1,075,375 shares.
ALHC Securities Notice: Alignment Healthcare Investors that Suffered Losses when Stock Plummeted 16% are Notified to Contact BFA Law about its Securities Fraud Investigation
Bleichmar Fonti & Auld LLP (BFA) has launched an investigation into Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud. This follows a 16.7% stock drop on July 8, 2026, after allegations surfaced that the company artificially inflated adjusted EBITDA to boost executive compensation. Investors who suffered losses are encouraged to contact BFA Law to discuss their legal options in a potential class action lawsuit.
ALHC Securities Notice: Alignment Healthcare Investors that Suffered Losses when Stock Plummeted 16% are Notified to Contact BFA Law about its Securities Fraud Investigation
Leading securities law firm Bleichmar Fonti & Auld LLP is investigating Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud. The investigation stems from allegations that Alignment artificially inflated adjusted EBITDA by misclassifying operating expenses as capital expenditures to boost executive compensation, leading to a 16.7% stock drop on July 8, 2026. Investors who suffered losses are encouraged to contact BFA Law to discuss their legal options.
ALHC Investor Notification: Alignment Healthcare Investigated for Securities Fraud on behalf of Investors with Losses after Inflated EBITDA Leads to 16% Stock Drop
Bleichmar Fonti & Auld LLP is investigating Alignment Healthcare, Inc. (NASDAQ:ALHC) for alleged securities fraud. The investigation follows a whistleblower lawsuit claiming the company artificially inflated adjusted EBITDA by misclassifying operating expenses as capital expenditures to boost executive compensation, leading to a 16.7% stock drop on July 8, 2026. Investors who suffered losses are encouraged to contact BFA Law to discuss their legal options.
ALHC Investor Notification: Alignment Healthcare Investigated for Securities Fraud on behalf of Investors with Losses after Inflated EBITDA Leads to 16% Stock Drop
Bleichmar Fonti & Auld LLP is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities fraud. This investigation follows allegations that the company artificially inflated its adjusted EBITDA to boost executive compensation, leading to a 16.7% stock drop on July 8, 2026. A whistleblower lawsuit claims that misclassifying routine operating expenses as capital expenditures allowed Alignment to report a positive adjusted EBITDA in 2024 instead of a significant loss.
A $40K tax-cover sale proposed by Alignment Healthcare (ALHC)'s chairman is not a discretionary trade.
Joseph Konowiecki, chairman of Alignment Healthcare (ALHC), has proposed selling 5,500 common shares valued at approximately $39,985, with an approximate sale date of November 10, 2026. This transaction is characterized as a "sale-to-cover" for tax withholding purposes rather than a discretionary trade. Konowiecki also reported a previous sale of 23,511 shares on September 17, 2026, for gross proceeds of $202,429.71.
Alignment Healthcare stock drops 16% amid securities fraud probe over inflated earnings
Alignment Healthcare's stock dropped 16.7% following allegations of securities fraud, specifically that the company inflated its adjusted EBITDA in 2024 by misclassifying $8-10 million in expenses to boost executive pay. A whistleblower lawsuit claims this misclassification turned a potential loss into a reported profit. The law firm Bleichmar Fonti & Auld is investigating the claims, urging investors to seek legal counsel regarding potential financial misreporting.
ALHC Stock Alert: Alignment Healthcare Stock Plummets 16%
Bleichmar Fonti & Auld LLP has launched an investigation into Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud. This comes after the company's stock dropped 16.7% on July 8, 2026, following allegations that Alignment artificially inflated adjusted EBITDA to boost executive compensation. A whistleblower lawsuit by a former CTO claims routine operating expenses were misclassified as capital expenditures, allowing the company to report a positive adjusted EBITDA in 2024 instead of a significant loss.
Alignment Healthcare, Inc. (ALHC) stock price, news, quote and history
Alignment Healthcare, Inc. (ALHC) stock closed at $7.34, down 2.91%, with an after-hours price of $7.34. The company, which operates a consumer-centric healthcare platform for seniors, has a market cap of $1.536 billion and a 1-year target estimate of $10.79. Its stock has seen significant declines year-to-date and over the past year, while analysts maintain a "Buy" rating with a lowered price target of $10.
Is Alignment Healthcare (ALHC) Undervalued After Raised Guidance And A Quarterly Loss?
Alignment Healthcare (ALHC) recently reported third-quarter results with higher revenue but a net loss, subsequently raising its full-year sales and membership guidance. This has led to a recent jump in its share price, despite significant declines over the past 90 days and year-to-date, suggesting a tension between growth potential and perceived profitability risks. The company is considered undervalued by some analyses, with its current price of $7.40 significantly below a fair value of $12.31, but a high P/E ratio signals that future performance heavily influences its valuation.
ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to Investors
Bleichmar Fonti & Auld LLP has announced an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities fraud. The investigation stems from allegations that Alignment artificially inflated its adjusted EBITDA to boost executive compensation, leading to a significant stock drop on July 8, 2026. Shareholders who invested in Alignment securities are encouraged to seek legal options.
ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to Investors
Bleichmar Fonti & Auld LLP is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities fraud. The investigation stems from allegations that the company artificially inflated its adjusted EBITDA by misclassifying operating expenses as capital expenditures to boost executive compensation. This alleged misrepresentation led to a significant 16.7% stock drop on July 8, 2026, after a whistleblower lawsuit brought these claims to light.
US$10.96: That's What Analysts Think Alignment Healthcare, Inc. (NASDAQ:ALHC) Is Worth After Its Latest Results
Alignment Healthcare, Inc. (NASDAQ:ALHC) recently reported its third-quarter results, exceeding revenue forecasts but leading to a 9.8% drop in share price. Analysts have since revised their earnings per share estimates downwards, resulting in an 11% reduction of the average price target to US$10.96, despite no major changes to revenue forecasts. The company is still expected to grow faster than the broader industry, but the lowered price target suggests increased pessimism about its intrinsic value.
UBS maintains Alignment Healthcare at Neutral, lowers price target to $8 from $9
UBS has reiterated its "Neutral" rating for Alignment Healthcare (ALHC) but reduced its price target to $8 from $9, an 11.1% decrease. This new target suggests a 10.0% upside from the stock's closing price of $7.27 on October 30. Recent analyst actions show price targets for ALHC ranging from $8 to $9 over the past 30 days.
Alignment Healthcare Price Target Cut to $8.00/Share From $9.00 by UBS
UBS has reduced its price target for Alignment Healthcare (ALHC) shares from $9.00 to $8.00. This adjustment reflects an updated outlook from the financial firm regarding the healthcare provider's stock performance.
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Alignment Healthcare, Inc. (ALHC) concerning potential breaches of fiduciary duties by its officers and directors. This probe follows reports of a whistleblower lawsuit alleging the company misclassified $8 million to $10 million in operating expenses as capital expenditures to inflate stock price and executive compensation. Further concerns arose after Alignment disclosed a downgrade in its Star Rating for a key contract, making it ineligible for quality bonus payments in fiscal 2028, leading to a significant decline in share price.
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Alignment Healthcare, Inc. (ALHC) following allegations of financial misclassification and a significant Star Rating downgrade by CMS. A whistleblower lawsuit claims the company deliberately misclassified $8 million to $10 million in operating expenses as capital expenditures to inflate its adjusted EBITDA and boost stock price and executive compensation. The investigation focuses on whether Alignment's officers and directors breached their fiduciary duties or violated state/federal laws, especially after the company's stock price declined following these disclosures.
Alignment Healthcare, Inc. Stock 12‑Month Price Target Cut to $10.96, Implies 36% Upside
Alignment Healthcare, Inc. (ALHC) has seen its average 12-month price target reduced from $12.31 to $10.96 by 12 analysts, despite the updated target still implying a 36% potential upside from its Oct. 29 closing price. The consensus rating for ALHC remains a "Buy" from 16 covering analysts.
Lost Money on Alignment Healthcare, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 16.7% Share Price Drop
Glancy Prongay Wolke & Rotter LLP is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for possible securities fraud after its stock price dropped 16.7% on July 8, 2026. This decline followed a whistleblower lawsuit alleging the company manipulated its finances by misclassifying operating expenses as capital expenditures to artificially inflate its adjusted EBITDA. Investors who lost money on Alignment Healthcare stock are encouraged to contact Glancy to learn about potentially recovering their losses.
Lost Money on Alignment Healthcare, Inc. Shares? The Law Offices of Frank R. Cruz Continues Investigating Potential Securities Fraud After 16.7% Stock Decline
The Law Offices of Frank R. Cruz is investigating potential securities fraud claims against Alignment Healthcare, Inc. following a 16.7% stock decline on July 8, 2026. This decline occurred after a whistleblower lawsuit alleged the company manipulated its finances by misclassifying operating expenses as capital expenditures to artificially inflate its adjusted EBITDA. Investors who lost money are encouraged to contact the firm for more information.
Revenue rises 36.7% as higher medical costs spur an outlook change at Alignment Healthcare (ALHC).
Alignment Healthcare (ALHC) reported a 36.7% increase in third-quarter 2026 revenue, reaching $1,358.3 million, and a 31.2% rise in health plan members to 301,200. Despite this growth, the company lowered its full-year adjusted gross profit and adjusted EBITDA guidance due to higher-than-expected medical costs experienced in the third quarter. The medical benefits ratio also increased to 89.5%, reflecting previously anticipated changes and higher costs in catastrophic cases and skilled nursing.
Alignment Healthcare, Inc. (ALHC) Reports In-Line Q3 EPS; offers guidance
Alignment Healthcare, Inc. (ALHC) reported its Q3 earnings per share (EPS) of ($0.04), which was in line with analyst estimates. The company's revenue for the quarter was $1.36 billion, exceeding the consensus estimate of $1.31 billion. ALHC also provided guidance for Q4 2026 revenue, projecting $1.316 billion, and reiterated its FY2026 revenue outlook at $5.245 billion.
Lost Money on Alignment Healthcare, Inc. Shares? The Law
The Law Offices of Frank R. Cruz is investigating potential securities fraud claims against Alignment Healthcare, Inc. (NASDAQ: ALHC) after its stock price declined by 16.7% on July 8, 2026. This decline followed reports of a whistleblower lawsuit alleging the company manipulated its finances by misclassifying operating expenses as capital expenditures, thereby inflating its adjusted EBITDA. Investors who lost money on Alignment Healthcare securities are encouraged to contact the firm to learn about potential claims.
Alignment Healthcare initiated with a Hold at Needham
Needham analyst Matthew Shea has initiated coverage of Alignment Healthcare (ALHC) with a Hold rating, citing the company's strong position to gain market share in Medicare Advantage. However, concerns exist regarding the downgrade of its largest California contract to 3.5 stars, which "clouds 2028 plan economics." The analyst also believes a favorable legal resolution is unlikely before bids are due.
Needham initiates Alignment Healthcare stock rating at Hold By Investing.com
Needham has initiated coverage on Alignment Healthcare Inc (NASDAQ:ALHC) with a Hold rating, noting the company's strong position in Medicare Advantage but highlighting concerns over its recent downgrade of its largest California contract to 3.5 stars. The stock has seen a significant decline in the past six months, and several other analysts have also downgraded the company due to utilization pressures, star rating losses, and increased cost expectations, despite analysts projecting profitability this year.
Needham Starts Alignment Healthcare Inc (ALHC) at Hold
Needham analyst Matthew Shea initiated coverage on Alignment Healthcare Inc (ALHC) with a Hold rating, citing the company's strong position in Medicare Advantage and its AVA technology. However, concerns about the downgrade of a major California contract, persistent institutional cost pressures, and elevated investments led to the cautious rating. The analyst awaits greater clarity on medical costs, earnings, and Star Ratings before adopting a more constructive stance.
Alignment Healthcare | 4: Statement of changes in beneficial ownership of securities-Officer Kim Hyong
This article, "Document," reports on a statement of changes in beneficial ownership of securities for Officer Kim Hyong at Alignment Healthcare. The content indicates a mandatory filing related to insider trading, though the specific details of the changes are not provided in the snippet.
$ALHC Stock Losses: BFA Law Reminds Alignment Healthcare Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Inflated EBITDA Misrepresentations
Bleichmar Fonti & Auld LLP is investigating Alignment Healthcare, Inc. (NASDAQ:ALHC) for potential securities fraud following a significant stock drop. The investigation centers on allegations that Alignment Healthcare artificially inflated adjusted EBITDA to boost executive compensation, specifically by misclassifying routine operating expenses as capital expenditures. This misclassification reportedly allowed the company to report a positive adjusted EBITDA in 2024 instead of a loss, leading to a 16.7% stock decline after a whistleblower lawsuit revealed the alleged misconduct.
Alignment Healthcare, Inc. Estimates – NASDAQ:ALHC
This article provides access to financial actuals and analyst estimates for Alignment Healthcare, Inc. (NASDAQ: ALHC) through TradingView. Users can explore reported financial data and compare it with average, high, and low estimates across various financial statements and valuation metrics. The platform allows for visualization of trends over time, covering income statements, balance sheets, and cash flow data on both annual and quarterly bases.
ALHC Investigation News: Alignment Healthcare Investors are
Bleichmar Fonti & Auld LLP has launched an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities fraud following a significant stock drop. The investigation centers on allegations that Alignment Healthcare artificially inflated its adjusted EBITDA by misclassifying operating expenses as capital expenditures to boost executive compensation, as revealed by a whistleblower lawsuit. This alleged misclassification allowed the company to report a positive adjusted EBITDA in 2024 instead of a loss, leading to a 16.7% stock decline on July 8, 2026, when the reports emerged.
Alignment Healthcare, Inc. (ALHC) Stock Forecasts
This article provides an Argus quantitative report for Alignment Healthcare Inc (ALHC), assigning it an Investment Rating of HOLD and a target price of $8.00. The report details subratings across various categories including Industry, Management, Safety, Financial Strength, Growth, and Value, most of which are rated Medium or Low. Readers are encouraged to upgrade for full access to premium research reports.
Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors
Alignment Health Plan announced a new Medicare Advantage plan for Pima County, Arizona, starting January 1, 2027, aiming to provide seniors with low-cost coverage, access to local providers, and bilingual support. This addition, Alignment Health ONE (HMO), strengthens the company's Arizona portfolio to seven plans, serving nearly 1.1 million Medicare beneficiaries across Maricopa, Pima, and Santa Cruz counties. The plans offer diverse options, including specialized support for chronic conditions and benefits like grocery allowances and $0 copays on many prescribed medications.
Alignment Healthcare's Planned Third-Quarter Dip Meets A Stock That Has Lost Nearly Half Its Value
Alignment Healthcare is facing investor scrutiny as its stock has fallen significantly despite management having forecast a soft third quarter due to strategic investments. The upcoming earnings report will focus on whether the company's planned slowdown and profitability dip align with its communicated strategy, particularly regarding its adjusted EBITDA and medical benefit ratio. Investors will look for confirmation that margins are being reinvested for future growth rather than reflecting unexpected medical cost increases.
Alignment Health Expands Medicare Advantage Plan to Nye County for 2027
Alignment Health (ALHC) is expanding its Medicare Advantage plan into Nye County, Nevada, effective January 1, 2027. This expansion extends their service area to include Clark, Nye, and Washoe counties, covering over 554,000 Medicare beneficiaries. The 2027 Nevada portfolio will feature six Medicare Advantage plans, supported by more than 6,500 physicians and including access to Intermountain Health.
Alignment Health Expands Medicare Advantage Plan to Nye County for 2027
Alignment Health Plan announced its expansion into Nye County, Nevada, starting January 1, 2027, making it available in three counties across the state. This expansion will offer new Medicare Advantage plan options to over 554,000 Medicare beneficiaries, including specialized plans for chronic conditions and benefits like grocery allowances and reduced Medicare Part B premiums. The company emphasizes its commitment to personalized care and strong provider relationships to help seniors navigate the healthcare system.
Alignment Health Expands Medicare Advantage Plan to Nye County for 2027
Alignment Health has announced an expansion of its Medicare Advantage plan into Nye County, Nevada, starting in 2027. This move aims to provide more healthcare options for seniors in the region, offering comprehensive benefits tailored to their needs. The expansion reflects Alignment Health's ongoing commitment to increasing access to quality and affordable healthcare for Medicare beneficiaries.
Alignment Health Plan Recognized Among U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage
Alignment Health Plan has been recognized by U.S. News & World Report as a 2027 Best Insurance Company for Medicare Advantage in all five states where it operates: Arizona, California, Nevada, North Carolina, and Texas. This marks the second consecutive year the company has received this "Best" rating in these markets and the seventh year overall for this recognition. The rating reflects Alignment's strong performance in care quality, prevention, and member satisfaction, based on CMS data and quality measures.
Alignment Health Plan Recognized Among U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage
Alignment Health Plan has been named a 2027 Best Insurance Company for Medicare Advantage by U.S. News & World Report in all five states where it operates: Arizona, California, Nevada, North Carolina, and Texas. This marks the second consecutive year Alignment has received this "Best" rating in these states, reflecting strong performance in care quality, prevention, and member satisfaction. The recognition is based on CMS data and quality measures, with U.S. News evaluating 31 quality measures relevant to consumers.
Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors
Alignment Health Plan and Astrana Health have partnered to expand access to primary and specialty care for Medicare Advantage beneficiaries across seven California counties, starting January 1, 2027. This collaboration aims to provide multilingual and culturally responsive care to California's diverse senior population through Astrana's network of over 9,500 providers. The partnership will support multiple Alignment plans, including the new Central Health Harmony HMO designed for Chinese-, Korean-, and Vietnamese-speaking seniors.
Medicare members in 7 California counties will gain access to 3,000 primary care providers and 6,500 specialists.
Alignment Health Plan and Astrana Health are partnering to expand in-network care access for Medicare Advantage beneficiaries across seven California counties, beginning January 1, 2027. This collaboration will provide members with access to Astrana’s network of 3,000 primary care providers and 6,500 specialists, including multilingual care options. The initiative aims to support California’s diverse senior population by offering culturally responsive care, particularly through plans like Central Health Harmony for Chinese-, Korean-, and Vietnamese-speaking seniors.
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Alignment Healthcare, Inc. (ALHC) concerning potential breaches of fiduciary duty by its officers and directors. This probe follows a whistleblower lawsuit alleging the company misclassified $8-10 million in operating expenses as capital expenditures to inflate its stock price and executive compensation. Further concerns arose after a CMS downgrade of Alignment's H3815 contract to 3.5 stars, making it ineligible for quality bonus payments in fiscal 2028, which led to a significant drop in share price.